Sharekhan's research report on Abbott India
Abbot reported a soft performance for the quarter reflecting the underperformance of acute therapies, while the earnings missed estimates. Abbott’s topline is expected to grow in double digits, backed by strong performance of its power brands and a sturdy new product pipeline. Better growth prospects backed by a revival in the acute therapies, a strong balance sheet position because of debt-free status and moderate capex coupled with healthy operating cash flows are the key positives.
Outlook
We retain our Buy recommendation on the stock of Abbot India Limited (Abbott) with an unchanged PT of Rs 19425.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
Read More
